Abstract Library
Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.
Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.
ENETS Abstract Search
#4593 Excellent response to Ac-225 DOTATATE therapy in a patient with small cell lung cancer
Introduction: Peptide receptor radionuclide therapy (PRRT) is a validated treatment for patients with NETs overexpressing somatostatin receptors (SSTR). IHC analysis indicates that up to 50% of small cell lung cancer (SCLC) tumours are SSTR2 positive and thus can be targeted by SSR imaging and PRRT. Therapy with α-emitting radionuclides, such as Ac225, may offer several advantages over β-emitters by having higher energy transfer and more effective cancer cell death.
Conference:
Presenting Author: Tuncel M
Authors: Tuncel M, Türkan C, Eryılmaz Y, Pala A, Kılıçkap S,
Keywords: Ac-225 DOTATATE, Small Cell lung cancer, PET, somatostatin receptor, PRRT,
#4521 [18F]FDG (FDG) PET/CT metrics as prognostic biomarkers in the AGITG NABNEC trial
Introduction: NABNEC was a prospective phase II trial investigating carboplatin/nab-paclitaxel in patients with advanced Grade 3 NENs (NCT02215447).
Conference:
Presenting Author: Kong G
Authors: Kong G, Ayati N, Brown C, Siu D, Mak W,
Keywords: Prognostic marker, prospective trial, chemotherapy, PET imaging, FDG, metabolic tumour volume, suv,
#4449 Treatment of MiNEN with peptide receptor radionuclide therapy
Introduction: Mixed non-neuroendocrine and neuroendocrine neoplasms (MiNENs) of gastrointestinal tract are rare tumours with characteristic histological features include at least 30% of both neuroendocrine and non-neuroendocrine components of the whole neoplasm. They are usually treated with surgical resection and chemotherapy in advanced disease. However, there is scarcity of data for the use of peptide receptor radionuclide therapy (PRRT) in these tumours.
Conference:
Presenting Author: Shekhda K
Authors: Shekhda K, Luong T, Paterson A, Navalkissoor S, Krell D,
Introduction: Paragangliomas (PGLs) are rare neuroendocrine tumours with variable clinical outcomes. Early identification of prognostic markers is essential for effective disease management. PET/CT imaging with 68Ga-DOTANOC, 18F-DOPA, and 18F-FDG offers unique insights into tumour biology, respectively.
Conference:
Presenting Author: Xu J
Authors: Gao J, Xu J, Liang Y, Chen J, Song S,
Keywords: PET/CT, paraganglioma, prognosis,
#4340 Predominant volumetric phenotype in dual PET and overall survival in NENs
Introduction: Dual 18F-FDG/68Ga-DOTATATE PET can predict NEN prognosis and guide treatment choice. However, research to date (such as the NEPTET score) has focused on the dual PET phenotype of single-point lesions rather than of the total disease volume.
Conference:
Presenting Author: Chan D
Authors: Chan D, Bernard E, Mokhtar S, Chou A, Gill A,
Keywords: Prognostic biomarker, PET/CT, tumour volume, 18F-FDG, 68Ga-DOTATATE,